SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

20 May 2022 Evaluate
The turnover zoomed to Rs. 276.83 millions, up 55.34% for the March 2022 quarter as against Rs. 178.21 millions during the year-ago period.The Net Loss for the quarter ended March 2022 is Rs. -152.35 millions as compared to Net Profit of Rs. 2.33 millions of corresponding quarter ended March 2021Operating Profit saw a handsome growth to 122.22 millions from 63.07 millions in the quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 276.83 178.21 55.34 1643.49 622.63 163.96 1643.49 622.63 163.96
Other Income 6.60 8.48 -22.17 27.20 22.10 23.08 27.20 22.10 23.08
PBIDT 122.22 63.07 93.78 1002.19 166.35 502.46 1002.19 166.35 502.46
Interest 29.10 63.05 -53.85 199.21 255.53 -22.04 199.21 255.53 -22.04
PBDT 65.09 -16.94 -484.24 756.30 -103.47 -830.94 756.30 -103.47 -830.94
Depreciation 91.31 19.50 368.26 153.89 80.50 91.17 153.89 80.50 91.17
PBT -26.22 -36.44 -28.05 602.41 -183.97 -427.45 602.41 -183.97 -427.45
TAX 126.13 -38.77 -425.33 203.38 -39.36 -616.72 203.38 -39.36 -616.72
Deferred Tax 126.13 -38.77 -425.33 203.38 -39.36 -616.72 203.38 -39.36 -616.72
PAT -152.35 2.33 -6638.63 399.03 -144.61 -375.94 399.03 -144.61 -375.94
Equity 286.90 286.90 0.00 286.90 286.90 0.00 286.90 286.90 0.00
PBIDTM(%) 44.15 35.39 24.75 60.98 26.72 128.24 60.98 26.72 128.24

Lyka Labs Share Price

58.16 0.56 (0.97%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×